바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.68 No.1
Citation Share

Immunohistochemical Expression and Prognostic Value of VEGF, HIF-1α, EGFR in Non-Small Cell Lung Cancer

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2010, v.68 no.1, pp.22-28



& (2010). Immunohistochemical Expression and Prognostic Value of VEGF, HIF-1α, EGFR in Non-Small Cell Lung Cancer. Tuberculosis & Respiratory Diseases, 68(1), 22-28.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis. VEGF production is regulated by HIF-1α and EGFR. This study examined the relationship between the clinicopathological factors and VEGF, HIF-1α and EGFR protein overexpression, and evaluated their prognostic value in patients with a surgically resected non-small cell lung cancer (NSCLC). Methods: Patients who underwent a surgical resection at Kangnam St. Mary’s hospital were reviewed retrospectively. The core biopsy samples from 54 patients with NSCLC were assembled on a tissue microarray (TMA), and immunohistochemical staining for the VEGF, HIF-1α and EGFR proteins was performed. The overexpression of these proteins was evaluated in relation to age, gender, histology and staging by univariate analysis. The clinicopathological prognostic factors were analyzed. Results: Multivariate analysis performed by Cox regression (odds ratio 2.8, 95% CI 1.0∼8.2, p=0.046) revealed HIF-1α overexpression to be an unfavorable factor. There was no correlation between the overexpression of these proteins and the clinicopathological factors. VEGF showed a positive relationship with EGFR, but there was no statistical significance [p(χ2)=0.06]. Conclusion: HIF-1α overexpression predicts shorter survival in patients with a surgically resected NSCLC. Therefore, HIF-1α may be a poor prognostic factor in NSCLC.

keywords
Carcinoma, Non-Small-Cell Lung, Immunohistochemistry, Prognosis

Reference

1.

1. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer:a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800.

2.

2. Onn A, Herbst RS. Angiogenesis and lung cancer: implications for prognosis and treatment. Lancet Oncol 2007;8:460-1.

3.

3. Bremnes RM, Camps C, Sirera R. Angiogenesis in nonsmall cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-58.

4.

4. Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.Ann Surg Oncol 2001;8:72-9.

5.

5. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z.Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.

6.

6. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.J Clin Oncol 2005;23:1011-27.

7.

7. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-40.

8.

8. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1).Mol Pharmacol 2006;70:1469-80.

9.

9. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-43.

10.

10. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.

11.

11. Maity A, Pore N, Lee J, Solomon D, O’Rourke DM.Epidermal growth factor receptor transcriptionally upregulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3’-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-86.

12.

12. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006;66:3197-204.

13.

13. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable nonsmall cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001;85:881-90.

14.

14. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.

15.

15. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.

16.

16. Cho SR, Byun JH, Kim JI, Lee BG, Chun BK. Expression of hypoxia-inducible factor-1alpha in non-small cell lung cancer: relationship to prognosis and tumor biomarkers.Korean J Thorac Cardiovasc Surg 2006;39:828-37.

17.

17. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma:a prospective study. J Natl Cancer Inst 1997;89:881-6.

18.

18. Yilmaz A, Ernam D, Unsal E, Demirag F, Atikcan S, Tastepe I. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res 2007;38:764-8.

19.

19. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K.Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer:a meta-analysis. Thorax 2006;61:140-5.

20.

20. Ahn JH, Kim SW, Hong SM, Suh C, Kim WK, Lee IC,et al. Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma. J Korean Med Sci 2004;19:529-35.

21.

21. Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15:28-32.

22.

22. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002;20:975-81.

23.

23. Battifora H. The multitumor (sausage) tissue block:novel method for immunohistochemical antibody testing.Lab Invest 1986;55:244-8.

24.

24. Schmidt LH, Biesterfeld S, Kummel A, Faldum A,Sebastian M, Taube C, et al. Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res 2009;29:201-9.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy